SCHEMBL288345

SCHEMBL288345

CC(C)[C@H](N)CCC(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 2/20 0.65
GABRD O14764 2/20 0.65
GABRA1 P14867 2/20 0.65
GABRB1 P18505 2/20 0.65
GABRG2 P18507 2/20 0.65
GABRB3 P28472 2/20 0.65
GABRA5 P31644 2/20 0.65
GABRA3 P34903 2/20 0.65
GABRA2 P47869 2/20 0.65
GABRB2 P47870 2/20 0.65
GABRA4 P48169 2/20 0.65
GABRE P78334 2/20 0.65
GABRA6 Q16445 2/20 0.65
GABRG1 Q8N1C3 2/20 0.65
GABRG3 Q99928 2/20 0.65
GABRQ Q9UN88 2/20 0.65
CYP1A2 P05177 2/20 0.52
GRM8 O00222 1/20 0.52
GRM6 O15303 1/20 0.52
GRIN2D O15399 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL932317 1.00 GABRP (0.65) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL4037012 1.00 GABRP (0.65) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL7350338 0.86 GABRP (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL7353965 0.86 GABRP (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL1427397 0.86 GABRP (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL1162283 0.85 GABRP (0.65) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL18980778 0.85 GABRP (0.65) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL26547294 0.84 ALDH1A1 (0.55) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8513633 0.84 GABRP (0.58) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL15871670 0.83 GABRP (0.62) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017481-B2 Conformationally constrained, fully synthetic macrocyclic compounds POLYPHOR AG (CH) 2018-07-10 US claimed
EP-2836485-B1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2018-01-10 EP claimed
US-9695191-B2 Conformationally constrained, fully synthetic macrocyclic compounds POLYPHOR AG (CH) 2017-07-04 US claimed
EP-2499148-B1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2017-01-18 EP claimed
US-9512139-B2 Conformationally constrained, fully synthetic macrocyclic compounds POLYPHOR AG (CH) 2016-12-06 US claimed
US-20150051183-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2015-02-19 US claimed
EP-2836485-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS Polyphor Ag (CH) 2015-02-18 EP claimed
EP-2462147-B1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2014-11-12 EP claimed
WO-2013139697-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2013-09-26 WO claimed
US-20120270881-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2012-10-25 US claimed
EP-2499148-A2 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS Polyphor Ag (CH) 2012-09-19 EP claimed
US-20120202821-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2012-08-09 US claimed
WO-2011014973-A2 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2011-02-10 WO claimed
US-20260144888-A1 USE OF A LIQUID AQUEOUS COMPOSITION FOR SOLUBILIZATION AND STABILIZATION OF AN ANTIBODY-DRUG CONJUGATE PIERRE FABRE MEDICAMENT (FR) 2026-05-28 US disclosed
EP-3697208-B1 HIGH-FIDELITY LONG-TERM STORAGE OF BIOLOGICAL MATERIAL CENTRE NAT RECH SCIENT (FR) 2026-04-22 EP disclosed
EP-4687443-A1 METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE Genepep (FR) 2026-02-11 EP disclosed
WO-2010127704-A1 BETA-HAIRPIN PEPTIDOMIMETICS HAVING CXCR4 ANTAGONIZING ACTIVITY POLYPHOR AG (CH) 2010-11-11 WO disclosed
WO-2010023295-A1 PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-03-04 WO disclosed
US-20080249030-A1 Age Inhibitors CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2008-10-09 US disclosed
CN-101268093-A Age inhibitors PHARMAMENS (FR) 2008-09-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202821-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS HTR2B, MC1R, HTR1A GABRP 301/4885GABRD 428/4885GABRA1 605/4885
US-20260144888-A1 USE OF A LIQUID AQUEOUS COMPOSITION FOR SOLUBILIZATION AND STABILIZATION OF AN ANTIBODY-DRUG CONJUGATE IGF1R, CD44, MUC1 GABRP 250/4885GABRD 807/4885GABRA1 242/4885
US-10017481-B2 Conformationally constrained, fully synthetic macrocyclic compounds CTSE, CTSB, CTSS GABRP 1165/4885GABRD 1253/4885GABRA1 916/4885
US-20120270881-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS KCNB1, KCNAB1, KCNMB1 GABRP 524/4885GABRD 1187/4885GABRA1 871/4885
US-20150051183-A1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS CTSE, CTSB, CTSS GABRP 1165/4885GABRD 1253/4885GABRA1 916/4885
US-20080249030-A1 Age Inhibitors CFH, XPA, XPNPEP1 GABRP 4639/4885GABRD 4878/4885GABRA1 4507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.